The estimated Net Worth of Donald C. Manning is at least 307 千$ dollars as of 8 June 2021. Donald Manning owns over 2,600 units of Adynxx stock worth over 2$ and over the last 6 years he sold ADYX stock worth over 306,810$. In addition, he makes 0$ as Chief Medical Officer at Adynxx.
Donald has made over 2 trades of the Adynxx stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,600 units of ADYX stock worth 158,964$ on 8 June 2021.
The largest trade he's ever made was selling 2,600 units of Adynxx stock on 8 June 2021 worth over 158,964$. On average, Donald trades about 996 units every 1 days since 2019. As of 8 June 2021 he still owns at least 23,520 units of Adynxx stock.
You can see the complete history of Donald Manning stock trades at the bottom of the page.
Dr. Donald C. Manning M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Donald C. Manning joined Adynxx in January 2012 continuing a 14 year career in the pharmaceutical industry where he has held positions of increasing scope and responsibility starting at Novartis as Global Head of Analgesics Development to Vice President and Neurosciences Therapeutic Area Head at Celgene, Vice President and Head of Clinical Development at Alpharma, VP of Medical Affairs at King Pharma and Executive Vice President and Chief Medical Officer at Shionogi Inc. Don received his BSc in Physiology and Biochemistry from McGill University in Montreal and earned his PhD in the laboratory of Dr. Solomon H. Snyder at Johns Hopkins University where he also earned his MD. He pursued residency training in Anesthesiology, fellowship training in Regional Anesthesia and Pain Management and a Post-Doctoral Fellowship in the Department of Neurosurgery under Dr. James Campbell all at Johns Hopkins. Before joining the pharmaceutical industry Don held clinical academic faculty positions in the Departments of Anesthesiology at Johns Hopkins, where he was co-director of the Pain Management Center and The University of Virginia Health Sciences Center. Don has lectured and published widely on pain management topics and is a past-president of the Eastern Pain Association, a regional affiliate of the American Pain Society.
Donald's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY, NJ, 07054.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Adynxx executives and other stock owners filed with the SEC include: